1,605 research outputs found

    An exact solution to the Dirac equation for a time dependent Hamiltonian in 1-1D space-time

    Full text link
    We find an exact solution to the Dirac equation in 1-1 dimensional space-time in the presence of a time-dependent potential which consists of a combination of electric, scalar, and pseudoscalar terms.Comment: Five page

    Scattering and bound states of spin-0 particles in a nonminimal vector double-step potential

    Full text link
    The problem of spin-0 particles subject to a nonminimal vector double-step potential is explored in the context of the Duffin-Kemmer-Petiau theory. Surprisingly, one can never have an incident wave totally reflected and the transmission amplitude has complex poles corresponding to bound states. The interesting special case of bosons embedded in a sign potential with its unique bound-state solution is analyzed as a limiting case.Comment: 1 figur

    Transport Properties of Solitons

    Get PDF
    We calculate in this article the transport coefficients which characterize the dynamics of solitons in quantum field theory using the methods of dissipative quantum systems. We show how the damping and diffusion coefficients of soliton-like excitations can be calculated using the integral functional formalism. The model obtained in this article has new features which cannot be obtained in the standard models of dissipation in quantum mechanics.Comment: 16 Pages, RevTeX, Preprint UIU

    Inconsistencies of a purported probability current in the Duffin-Kemmer-Petiau theory

    Full text link
    The Duffin-Kemmer-Petiau (DKP) equation with a square step potential is used in a simple way with polymorphic purposes. It proves adequate to refuse a proposed new current that is currently interpreted as a probability current,to show that the Klein paradox does exist in the DKP theory and to revise other minor misconceptions diffused in the literature.Comment: 11 page

    Nonleptonic two-body charmless B decays involving a tensor meson in ISGW2 model

    Full text link
    Nonleptonic charmless B decays into a pseudoscalar (P) or a vector (V) meson accompanying a tensor (T) meson are re-analyzed. We scrutinize the hadronic uncertainties and ambiguities of the form factors which appear in the literature. The Isgur-Scora-Grinstein-Wise updated model (ISGW2) is adopted to evaluate the relevant hadronic matrix elements. We calculate the branching ratios and CP asymmetries for various BP(V)TB\to P(V)T decay processes. With the ISGW2 model, the branching ratios are enhanced by about an order of magnitude compared to the previous estimates. We show that the ratios \calB(B\to VT)/\calB(B\to PT) for some strangeness-changing processes are very sensitive to the CKM angle γ\gamma (ϕ3\phi_3).Comment: 23 pages, REVTEX; minor clarifications included; to appear in Phys. Rev.

    Spinless bosons embedded in a vector Duffin-Kemmer-Petiau oscillator

    Get PDF
    Some properties of minimal and nonminimal vector interactions in the Duffin-Kemmer-Petiau (DKP) formalism are discussed. The conservation of the total angular momentum for spherically symmetric nonminimal potentials is derived from its commutation properties with each term of the DKP equation and the proper boundary conditions on the spinors are imposed. It is shown that the space component of the nonminimal vector potential plays a crucial role for the confinement of bosons. The exact solutions for the vector DKP oscillator (nonminimal vector coupling with a linear potential which exhibits an equally spaced energy spectrum in the weak-coupling limit) for spin-0 bosons are presented in a closed form and it is shown that the spectrum exhibits an accidental degeneracy

    A Pulsating Gaussian Wave Packet

    Get PDF
    A pulsating Gaussian wave packet for the harmonic oscillator is explicitly constructed. The mechanism for that behaviour is pointed out. © 1999 IOP Publishing Ltd.201L19L20Tsuru, H., (1992) J. Phys. Soc. Jpn., 61, p. 2595Goldman, I.I., Krivchenkov, V.D., Kogan, Galitskii, (1960) Selected Problems in Quantum Mechanics, , transl D ter Haar (London: Infosearch)Feynman, R.P., Hibbs, A.R., (1965) Quantum Mechanics and Path Integrals, , New York: McGraw-Hil

    Calculation of excited polaron states in the Holstein model

    Full text link
    An exact diagonalization technique is used to investigate the low-lying excited polaron states in the Holstein model for the infinite one-dimensional lattice. For moderate values of the adiabatic ratio, a new and comprehensive picture, involving three excited (coherent) polaron bands below the phonon threshold, is obtained. The coherent contribution of the excited states to both the single-electron spectral density and the optical conductivity is evaluated and, due to the invariance of the Hamiltonian under the space inversion, the two are shown to contain complementary information about the single-electron system at zero temperature. The chosen method reveals the connection between the excited bands and the renormalized local phonon excitations of the adiabatic theory, as well as the regime of parameters for which the electron self-energy has notable non-local contributions. Finally, it is shown that the hybridization of two polaron states allows a simple description of the ground and first excited state in the crossover regime.Comment: 12 pages, 9 figures, submitted to PR

    Estudo da mutação do recetor do fator de crescimento epidérmico, durante 5 anos, numa população de doentes com cancro do pulmão de não pequenas células

    Get PDF
    ResumoIntroduçãoEm 2006, a Unidade de Pneumologia Oncológica do Serviço de Pneumologia do Centro Hospitalar de Vila Nova de Gaia/Espinho iniciou a sequenciação da mutação do recetor do fator de crescimento epidérmico (EGFR) em doentes com CPNPC selecionados e desde 2010 realiza a sequenciação sistematicamente em todos os doentes, independentemente da histologia, hábitos tabágicos, idade ou sexo. O objetivo deste trabalho foi caracterizar o grupo de doentes que efetuou a sequenciação entre 2006-2010, determinar a frequência da mutação EGFR, avaliar as sobrevidas globais e após uso de inibidores da tirosina quinase (ITK), nos doentes que efetuaram esta terapêutica em 2.a e 3.a linha com conhecimento do estado da mutação do EGFR.MétodosAnálise estatística descritiva dos doentes que efetuaram sequenciação EGFR em 2006-2010 e sobrevida mediana global nos doentes que efetuaefetuaram ITK em 2.a e 3.a linha. Registo do material disponível para análise e demora média de resultado do exame, de acordo com o material enviado.ResultadosA sequenciação foi efetuada em 374 doentes, 71,1% sexo masculino, 67,1% não/ex-fumadores, 32,9% fumadores; 57,8% adenocarcinoma e 23,5% carcinoma epidermoide (CE). A mutação foi detetada em 49 doentes (13,1%). No total dos doentes estudados, a taxa de mutação foi de 9% no sexo masculino e 23% no sexo feminino. A sobrevida mediana global após o uso de erlotinib foi de 14 meses para os doentes com mutação positiva do EGFR versus 6 meses nos doentes não mutados (p = 0,003).ConclusãoO nosso grupo teve uma taxa de mutação global de 13,1%, com predomínio no sexo feminino, não fumadores, histologia adenocarcinoma. Em doentes selecionados (2006/2009), a taxa de mutação foi de 16%; nos doentes não selecionados (2010) foi de 10,4%. Este estudo tem vindo a permitir um melhor conhecimento da taxa de mutação do EGFR na população portuguesa, bem como avaliar os resultados das sobrevidas dos doentes após uso de inibidores da tirosina quinase (ITK), efetuada em 2.a e 3.a linha com conhecimento prévio do estado da mutação do EGFR, tendo sido encontradas diferenças nas sobrevidas nos 2 grupos de doentes (mutados e não mutados) com significado estatístico.A pesquisa mutação do EGFR deve ser efetuada em todos os doentes com CPNPC, dando possibilidade a um número considerável de doentes de poder efetuar um tratamento de 1.a linha com ITK (doentes mutados), bem como de poder usufruir de outros esquemas de quimioterapia, quando progredirem.AbstractIntroductionIn 2006, the Vila Nova de Gaia/Espinho Hospital Centre Pulmonary Oncology Unit started performing EGFR (Epidermal Growth Factor Receptor) mutation sequencing in selected patients with NSCLC and systematically in all patients since 2010, regardless of histology, smoking habits, age or sex. The aim of this study was to characterize the group of patients that carried out the sequencing between 2006-2010, to determine EGFR mutation frequency, to evaluate the overall survival and the survival after the use of tyrosine kinase inhibitors (TKI), in patients who performed this therapy in second and third line, knowing the EGFR mutation status.MethodsDescriptive statistical analysis of patients who did EGFR sequencing in 2006-2010 and of overall survival in patients treated with TKI as 2nd and 3rd line therapy. Record of the material available for analysis and average delay of exam results, according to the material submitted.ResultsThe sequencing was performed in 374 patients, 71,1% males, 67,1% non/ex-smokers, 32,9% smokers, 57,8% adenocarcinoma and 23,5% squamous cell carcinoma (SCC). The mutation was detected in 49 patients (13,1%). In all studied patients, the mutation rate was 9% in males and 23% in females. Median overall survival after erlotinib use of was 14 months for patients with positive EGFR mutation versus 6 months in not mutated patients (p = 0.003).ConclusionOur group had an overall mutation rate of 13.1% with female, non-smokers, adenocarcinoma histology predominance. In selected patients (2006/2009), the mutation rate was 16%, in not selected patients (2010) the mutation rate was 10.4%. This study has permitted a better understanding of the EGFR mutation rate in the Portuguese population as welll as an evaluation of the patients survival after the use of of tyrosine kinase inhibitors, in second and third line therapy with previous knowledge of the EGFR mutational status. Statistical significant differences in survival were found in the two patient groups (EGFR mutated and non mutated).The EGFR mutation research should be performed in all patients with NSCLC, giving the possibility to a considerable number of patients to perform a first line treatment with TKI (EGFR mutated patients) and the advantage of performing other chemotherapy schemes, when progression occurs
    corecore